Future Oncology
Volume 18, 2022 - Issue 31
Open access
3,587
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol
EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)
Panagiotis A Konstantinopoulos1 Dana-Farber Cancer Institute, Boston, MA02215, USACorrespondence[email protected]
https://orcid.org/0000-0002-1032-1479View further author information
, https://orcid.org/0000-0002-1032-1479View further author information
Antonio Gonzalez-Martin2 Clínica Universidad de Navarra & Program in Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, 31008, SpainView further author information
, Felipe Melo Cruz3 Núcleo de Pesquisa e Ensino da Rede São Camilo, São Paulo, 04014-002, BrazilView further author information
, Michael Friedlander4 Department of Medical Oncology, Prince of Wales Hospital & Prince of Wales Clinical School, University of New South Wales, Sydney, 2031, Australiahttps://orcid.org/0000-0003-3090-795XView further author information
, Rosalind Glasspool5 Beatson West of Scotland Cancer Centre & University of Glasgow, Glasgow, G12, UKhttps://orcid.org/0000-0002-5000-1680View further author information
, Domenica Lorusso6 Fondazione Policlinico Universitario A Gemelli IRCCS & Catholic University of Sacred Heart, Rome, 00168, Italyhttps://orcid.org/0000-0003-0981-0598View further author information
, Christian Marth7 Medizinische Universität Innsbruck, Innsbruck, 6020, Austriahttps://orcid.org/0000-0002-8965-9981View further author information
, Bradley J Monk8 HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ85012, USAView further author information
, Jae-Weon Kim9 Seoul National University, Seoul, 08826, South Koreahttps://orcid.org/0000-0003-1835-9436View further author information
, Patsy Hinson10 Ovarian Cancer Research Alliance (OCRA), New York, NY10122, USAView further author information
, Olga Ajipa11 Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USAView further author information
, Vincent Pretre11 Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USAView further author information
, Yu Han11 Novartis Pharmaceuticals Corporation, East Hanover, NJ07936, USAView further author information
& Ursula A Matulonis1 Dana-Farber Cancer Institute, Boston, MA02215, USAhttps://orcid.org/0000-0002-3103-6992View further author information
show all
Pages 3481-3492
|
Received 29 Jun 2022, Accepted 12 Aug 2022, Published online: 06 Sep 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.